Colorectal-cancer incidence and mortality with screening flexible sigmoidoscopy.

BACKGROUND The benefits of endoscopic testing for colorectal-cancer screening are uncertain. We evaluated the effect of screening with flexible sigmoidoscopy on colorectal-cancer incidence and mortality. METHODS From 1993 through 2001, we randomly assigned 154,900 men and women 55 to 74 years of age either to screening with flexible sigmoidoscopy, with a repeat screening at 3 or 5 years, or to usual care. Cases of colorectal cancer and deaths from the disease were ascertained. RESULTS Of the 77,445 participants randomly assigned to screening (intervention group), 83.5% underwent baseline flexible sigmoidoscopy and 54.0% were screened at 3 or 5 years. The incidence of colorectal cancer after a median follow-up of 11.9 years was 11.9 cases per 10,000 person-years in the intervention group (1012 cases), as compared with 15.2 cases per 10,000 person-years in the usual-care group (1287 cases), which represents a 21% reduction (relative risk, 0.79; 95% confidence interval [CI], 0.72 to 0.85; P<0.001). Significant reductions were observed in the incidence of both distal colorectal cancer (479 cases in the intervention group vs. 669 cases in the usual-care group; relative risk, 0.71; 95% CI, 0.64 to 0.80; P<0.001) and proximal colorectal cancer (512 cases vs. 595 cases; relative risk, 0.86; 95% CI, 0.76 to 0.97; P=0.01). There were 2.9 deaths from colorectal cancer per 10,000 person-years in the intervention group (252 deaths), as compared with 3.9 per 10,000 person-years in the usual-care group (341 deaths), which represents a 26% reduction (relative risk, 0.74; 95% CI, 0.63 to 0.87; P<0.001). Mortality from distal colorectal cancer was reduced by 50% (87 deaths in the intervention group vs. 175 in the usual-care group; relative risk, 0.50; 95% CI, 0.38 to 0.64; P<0.001); mortality from proximal colorectal cancer was unaffected (143 and 147 deaths, respectively; relative risk, 0.97; 95% CI, 0.77 to 1.22; P=0.81). CONCLUSIONS Screening with flexible sigmoidoscopy was associated with a significant decrease in colorectal-cancer incidence (in both the distal and proximal colon) and mortality (distal colon only). (Funded by the National Cancer Institute; PLCO ClinicalTrials.gov number, NCT00002540.).

[1]  L M Schuman,et al.  Reducing mortality from colorectal cancer by screening for fecal occult blood. Minnesota Colon Cancer Control Study. , 1993, The New England journal of medicine.

[2]  L. Terracciano,et al.  Characterization of rectal, proximal and distal colon cancers based on clinicopathological, molecular and protein profiles. , 2010, International journal of oncology.

[3]  Á. Lanas,et al.  Colonoscopy versus fecal immunochemical testing in colorectal-cancer screening. , 2012, The New England journal of medicine.

[4]  P. Prorok,et al.  The yield of surveillance colonoscopy by adenoma history and time to examination. , 2009, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[5]  S. Moss,et al.  Randomised controlled trial of faecal-occult-blood screening for colorectal cancer , 1989, The Lancet.

[6]  Cancer,et al.  Once-only flexible sigmoidoscopy screening in prevention of colorectal cancer: a multicentre randomised controlled trial , 2010, The Lancet.

[7]  P. Maisonneuve,et al.  Screening and surveillance for the early detection of colorectal cancer and adenomatous polyps. , 2008, Gastroenterology.

[8]  G. Izmirlian.  Estimation of the relative risk following group sequential procedure based upon the weighted log-rank statistic , 2011, 1102.5088.

[9]  P. Prorok,et al.  Colorectal cancers not detected by screening flexible sigmoidoscopy in the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial. , 2012, Gastrointestinal endoscopy.

[10]  T. Church,et al.  Colorectal cancer mortality: effectiveness of biennial screening for fecal occult blood. , 1999, Journal of the National Cancer Institute.

[11]  T. Stukel,et al.  Association between colonoscopy and colorectal cancer mortality in a US cohort according to site of cancer and colonoscopist specialty. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  Zhiliang Ying,et al.  A General Theory on Stochastic Curtailment for Censored Survival Data , 1999 .

[13]  B. Levin,et al.  Screening and surveillance for the early detection of colorectal cancer and adenomatous polyps, 2008: a joint guideline from the American Cancer Society, the US Multi-Society Task Force on Colorectal Cancer, and the American College of Radiology. , 2008, Gastroenterology.

[14]  H. Brenner,et al.  Protection From Colorectal Cancer After Colonoscopy , 2011, Annals of Internal Medicine.

[15]  A. Jemal,et al.  Cancer statistics, 2011 , 2011, CA: a cancer journal for clinicians.

[16]  B. Leggett,et al.  Role of the serrated pathway in colorectal cancer pathogenesis. , 2010, Gastroenterology.

[17]  T. Church,et al.  The effect of fecal occult-blood screening on the incidence of colorectal cancer. , 2000, The New England journal of medicine.

[18]  J. Gohagan,et al.  Cumulative Incidence of False-Positive Results in Repeated, Multimodal Cancer Screening , 2009, The Annals of Family Medicine.

[19]  P. Glasziou,et al.  Cochrane Systematic Review of Colorectal Cancer Screening Using the Fecal Occult Blood Test (Hemoccult): An Update , 2008, The American Journal of Gastroenterology.

[20]  L. Bisanti,et al.  Once-only sigmoidoscopy in colorectal cancer screening: follow-up findings of the Italian Randomized Controlled Trial--SCORE. , 2011, Journal of the National Cancer Institute.

[21]  Rinku Sutradhar,et al.  Analysis of administrative data finds endoscopist quality measures associated with postcolonoscopy colorectal cancer. , 2011, Gastroenterology.

[22]  J. Habbema,et al.  Screening for colorectal cancer: randomised trial comparing guaiac-based and immunochemical faecal occult blood testing and flexible sigmoidoscopy , 2009, Gut.

[23]  P C Prorok,et al.  Design of the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial. , 2000, Controlled clinical trials.

[24]  O. Kronborg,et al.  Randomized study of biennial screening with a faecal occult blood test: results after nine screening rounds , 2004, Scandinavian journal of gastroenterology.

[25]  L. Rabeneck,et al.  Risk of developing proximal versus distal colorectal cancer after a negative colonoscopy: a population-based study. , 2008, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[26]  M. Fouad,et al.  Recruitment strategies in the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial: the first six years. , 2000, Controlled clinical trials.

[27]  S. Kakar,et al.  Proximal and distal colorectal cancers show distinct gene-specific methylation profiles and clinical and molecular characteristics. , 2008, European journal of cancer.

[28]  A. Miller,et al.  Death review process in the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial. , 2000, Controlled clinical trials.

[29]  R. Pearson,et al.  Utilization of Surveillance Colonoscopy in Community Practice , 2010 .

[30]  R. Pearson.  Association of Colonoscopy and Death from Colorectal Cancer , 2009 .

[31]  L. Bisanti,et al.  Comparing attendance and detection rate of colonoscopy with sigmoidoscopy and FIT for colorectal cancer screening. , 2007, Gastroenterology.

[32]  M. Bretthauer,et al.  Risk of colorectal cancer seven years after flexible sigmoidoscopy screening: randomised controlled trial , 2009, BMJ : British Medical Journal.

[33]  N. Dubrawsky.  Cancer statistics , 1989, CA: a cancer journal for clinicians.

[34]  E. Kliewer,et al.  The reduction in colorectal cancer mortality after colonoscopy varies by site of the cancer. , 2010, Gastroenterology.

[35]  I. Forgacs.  GASTROENTEROLOGY , 1988, The Lancet.

[36]  Harminder Singh,et al.  Predictors of Colorectal Cancer After Negative Colonoscopy: A Population-Based Study , 2010, The American Journal of Gastroenterology.

[37]  Bernadette Mazurek Melnyk,et al.  Screening for colorectal cancer: U.S. Preventive Services Task Force recommendation statement. , 2008, Annals of internal medicine.

[38]  J. Cooper.  Ajcc Cancer Staging Manual , 1997 .

[39]  P. Prorok,et al.  Flexible sigmoidoscopy in the randomized prostate, lung, colorectal, and ovarian (PLCO) cancer screening trial: added yield from a second screening examination. , 2012, Journal of the National Cancer Institute.

[40]  L. Rabeneck,et al.  Association of Colonoscopy and Death From Colorectal Cancer , 2009, Annals of Internal Medicine.

[41]  D L DeMets,et al.  The alpha spending function approach to interim data analyses. , 1995, Cancer treatment and research.

[42]  J. Gohagan,et al.  Flexible sigmoidoscopy in the PLCO cancer screening trial: results from the baseline screening examination of a randomized trial. , 2005, Journal of the National Cancer Institute.

[43]  Anders Ahlbom,et al.  Biostatistics for Epidemiologists , 1993 .